Esther De La Cuesta, MD, MBA
Pediatric Advisor/ Senior Clinical Development Leader
Oncology, Clinical Development and Operations, Bayer Pharmaceuticals Inc.
Dr. Esther De La Cuesta has extensive experience in the Pharmaceutical Industry that spans 27 years across multiple therapeutic areas including Oncology, Cardiovascular and Immunology. She has experiences in drug development through all development phases, Medical Affairs, Business Development and Pharmacovigilance to support submissions, product launches and post marketing activities.
She has held positions of increasing responsibility and of strategic importance at Rhone Poulenc Rorer (Aventis), ICON, COVANCE, Bristol Myers Squibb, Abbott (AbbVie), Vertex and Takeda where she led the strategic geographical expansions for established products to emerging markets before joining Bayer in 2017 as (Senior Director) Therapeutic Area Head – Oncology in Benefit Risk Management. After years in Pharmacovigilance, she decided to rejoin Clinical Research and Development as Senior Clinical Development Leader for the Larotrectinib pediatric program in the SBU Oncology as well as the Regorafenib pediatric studies. In addition, she is the Pediatric Advisor, Oncology Development within Clinical Development and Operation, Oncology.
She was a key contributor to 2 successful NDAs (ODAC) and 1 successful EMDAC; and has global experience with effective communications/interactions with multiple Regulatory Authorities e.g., FDA, EMA, HC, MHRA, PMDA and BfArM.
Dr. De La Cuesta obtained her MD from the University of St. Thomas in the Philippines and has a Master’s Degree in Business Administration (MBA), Healthcare from Penn State University.